Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Investing Activities (2023 - 2025)

Kura Oncology (KURA) has disclosed Cash from Investing Activities for 3 consecutive years, with -$64.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 31.97% to -$64.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.1 million, a 87.11% increase, with the full-year FY2025 number at -$13.1 million, up 87.11% from a year prior.
  • Cash from Investing Activities was -$64.6 million for Q4 2025 at Kura Oncology, down from $94.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $94.0 million in Q3 2025 to a low of -$101.4 million in Q1 2025.
  • A 3-year average of -$8.3 million and a median of $9.8 million in 2023 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 432.01% in 2024; the steepest drop was 956.65% in 2024.
  • Kura Oncology's Cash from Investing Activities stood at $42.2 million in 2023, then tumbled by 325.04% to -$95.0 million in 2024, then skyrocketed by 31.97% to -$64.6 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Cash from Investing Activities are -$64.6 million (Q4 2025), $94.0 million (Q3 2025), and $58.9 million (Q2 2025).